MUC16 and ovarian cancer: However, CA125 has proven to be a poor diagnostic tumor biomarker because it lacks specificity and sensitivity for early ovarian cancer (only 23% in stage I ovarian cancer, in contrast to more than 80% in advanced ovarian cancer) [11].